Menu Close

ILC 2023 – Archived

Celebrating the Success of the ILC Symposium 2023!

Thank you for your enthusiastic participation in the ILC Symposium 2023. Your presence, diverse perspectives, and unwavering support played a pivotal role in making the symposium a resounding success. Our thanks to all researchers, patient advocates, and clinicians for their active involvement.

We were honored to have hosted 221 attendees in person and 51 virtually, creating a vibrant global exchange of knowledge. The symposium was enriched by the participation of individuals from 15 different countries, fostering a truly international dialogue.

Together, we’re advancing understanding of ILC, improving treatments, and enhancing support for those affected. We look forward to the positive outcomes and collaborations arising from this symposium.

With warm regards,

Organizing Committee ILC 2023

Watch the recorded sessions below

Thank you to the presenters who agreed to record and share their presentations.  Not all presentations were recorded. Please contact the presenters directly with questions. For the complete agenda, click here.

Keynote Speakers

Speakers, Chairs, & Moderators

Agenda – Click here for PDF

Abstract Booklet – Click here for PDF

ILC 2023 Posters

The poster PDFs provided here have been shared with the consent of the authors. This collection includes poster PDFs for 29 out of 50 posters, depending on which authors granted permission for their poster PDFs to be published.

1Gitte ZelsOverview of patients with invasive lobular breast carcinoma included in the post-mortem tissue donation program, UPTIDERClinical
2Qian ZhaoClinical Characteristics and Outcomes of Invasive Lobular CarcinomaClinical
3Jasmine TimbresRisk factors pre-disposing to LCIS and ILCClinical
4Josephine Van CauwenbergeReporting on invasive lobular carcinoma in clinical drug trials and trials investigating gene expression profiles and molecular screening programs – a systematic reviewClinical
5Siobhan FreeneyEnhancing Knowledge and Research in Europe for Invasive Lobular Breast Cancer: Unique Challenges across European CountriesClinical
6Helen Coulthard“they… kept saying there’s nothing there”: British Women’s accounts of delayed lobular breast cancer diagnosisDiagnosis
7Laurie HutchesonIndividuals with Invasive Lobular Carcinoma (ILC) Raise their Voices about ILC and SurgeryDiagnosis
8Luca NicosiaContrast-Enhanced Mammography (CEM) compared to Breast Magnetic Resonance (MRI) in the management of breast lobular neoplasia: a new scenario in facing the diagnosis of an insidious diseaseDiagnosis
10Annapurna GuptaDownregulation of Arginosuccinate synthase 1 confers Tamoxifen Resistance in Invasive Lobular Breast CancerTreatment
11Bernadette Heemskerk-GerritsenThe effect of (neo)adjuvant chemotherapy on long-term survival outcomes in Invasive Lobular Breast Cancer Patients treated with endocrine therapy: a retrospective cohort studyTreatment
13Christina GerschCharacterization of Resistance to CDK4/6 Inhibitors and Endocrine Therapy in Invasive Lobular Breast Cancers Cell LinesTreatment
16Melinda SandersHigh prevalence of HER2-low among ILC with residual disease following neoadjuvant therapy provides therapeutic opportunities with HER2-antibody-drug conjugatesTreatment
17William YangE-cadherin loss imparts mitotic vulnerabilities rendering breast cancer cells synthetic lethal to crizotinib and up-regulation of Src signalling reverses this effectTreatment
20Francesca MagnoniComparison of long-term outcome between high risk lobular versus ductal breast cancer: a propensity score matched studyPrognosis
21Rebecca RigginsGlutamate metabolic enzymes associate with increased tumor size in black women with invasive lobular breast cancer: a single-institution studyPrognosis
22Simran SandhuRacial Disparities in Survival in Lobular Breast CancerPrognosis
23Baylee PorterGlucocorticoid receptor activation inhibits tumor cell growth while increasing metastatic characteristics in models of invasive lobular breast cancerMetastasis
24Bernadette Heemskerk-GerritsenLocalization of metastatic disease in patients with a history of lobular carcinoma of the breastMetastasis
27Andi CaniSerial monitoring of circulating tumor cells and circulating tumor DNA in metastatic lobular breast cancer identifies intra-tumor heterogeneity and precision and immuno-oncology biomarkers of therapeutic importanceBiomarker
28Chinasa A UfonduAssessing the Effect of E-cadherin loss on Estrogen Receptor activity in Human Mammary Epithelial Cell ModelsBiomarker
30Luyu JiaMutating E-cadherin in Rats to Model Lobular Breast CancerBiomarker
31Madeleine ShacklefordWNT4 regulates cellular metabolism via intracellular activity at the mitochondria in invasive lobular carcinoma cellsBiomarker
32Maggie MusickE-cadherin suppression supports transcriptional programs of
lineage plasticity in early ILC tumorigenesis
36Matteo SerraSpatially resolved analysis of tumor microenvironment revealed biologically driven subgroups with distinct clinical outcome in invasive lobular carcinomaTME
37Emmanuelle mouret-fourmeClinical Characteristics of Lobular Breast Carcinoma in CDH1 genetic predisposition. Experience from the Institut CurieGenetics
40Rita Canas-MarquesAberrant E-cadherin (E-cad) Expression in Lobular Carcinoma in Situ (LCIS): A Comprehensive Evaluation of N-terminal, Extracellular, and C-terminal E-cadherin DomainsGenetics
41Jing YuLobular-like invasive mammary carcinoma: Is this a ductal cancer, lobular cancer, or a distinct entity?Genetics
44Sanghoon LeeChromatin accessibility landscape and active transcription factors in primary human invasive lobular and ductal breast carcinomasEpigenomics
48Sarah NashTranscriptomic and immune heterogeneity underpin the biology of pleomorphic invasive lobular breast cancerMultiomics

Travel Fellowship Awardees

We are thrilled to announce the distinguished recipients of the Travel Fellowship for the upcoming ILC Symposium 2023. These exceptional individuals have demonstrated outstanding dedication and contributions to the field of invasive lobular breast cancer research.

Awardees attending from within the USA will receive $800, while international attendees will receive $1200 in fellowship amounts. These fellowships aim to assist participants in covering their expenses and fostering a diverse and inclusive environment for knowledge exchange.

Join us in congratulating the following scholars who have been selected to receive the prestigious Travel Fellowship Award, listed below and here.

Their commitment and passion exemplify the spirit of collaboration and knowledge-sharing that the ILC Symposium stands for. We eagerly anticipate their participation and look forward to their valuable contributions at the symposium.
We extend our heartfelt appreciation to all applicants for their exceptional submissions and encourage everyone to be part of this inspiring event.

For Breast Cancer Advocates

CLICK HERE for the ILC Workshop Agenda.

Presentations from the Symposium

Session 1 Slides

Digital Toolkit for Advocates

We are delighted to present the “Digital Toolkit for Advocates” designed exclusively for patient advocates attending the ILC Symposium 2023. This comprehensive toolkit is aimed at enhancing your symposium experience by providing valuable resources and empowering you in your advocacy journey.

Inside the toolkit, you’ll find a treasure trove of resources, including:

📽️ Video Recordings: Access video recordings of past symposium sessions to catch up on valuable insights shared by renowned experts in the field.

🎧 Instructive Recordings: Dive deeper into instructive sessions that offer valuable tips and advice on patient advocacy, communication, and empowerment.

🔗 Links to Advocacy Resources: Discover a curated collection of links to advocacy resources, including Facebook groups and other online platforms where you can connect with like-minded advocates.

💡 Useful Resources: Find a compilation of valuable resources, documents, and informative materials that can aid you in your advocacy efforts.

This Digital Toolkit is your companion throughout the symposium and beyond, offering a wealth of knowledge and support to enhance your advocacy journey. We hope these resources empower you to make a positive impact in the field of invasive lobular breast cancer research.

Click here to access the Digital Toolkit for Advocates

International Organizing Committee

Local Organizing Committee

GlobMob (Patient Advocate) Organizing Committee


The Assembly

5051 Centre Avenue
Pittsburgh, PA 15213

A historical venue to create memories: The ILC symposium 2023 will be held at The Assembly building in Pittsburgh. This is a unique venue with a rich history unlike any other. A century ago, The Assembly was Ford automotive’s first Model T assembly plant in the US. Over the years the building has become a clothing store and a stationary store. Today, the building has been transformed into a cutting-edge research facility, housing researchers working on cancer and other diseases. We hope this venue will facilitate innovative ideas, new collaboration and relationships, and many priceless memories. Read more on the fascinating history of the venue here: The Assembly: A former Model T factory builds the next generation of cancer treatments

Then and now


Platinum Level

Gold Level

Silver Level

Bronze Level

Institutional Support